Cell Culture Technologies is a private Swiss biotech company founded in 1992 by Ferruccio Messi, Ph.D. The company offers technology transfer programs to generate recombinant glycoproteins, monoclonal antibodies, viral particles and cells in fully synthetic culture environments. The European Collection of Cell Cultures (ECACC) has been distributing several serum-free adapted mammalian cell lines banked in minimal media developed and manufactured by Cell Culture Technologies since 2003. Furthermore, a number of biopharma companies developed product pipelines by cultivating CHO cells and hybridomas in Cell Culture Technologies’ minimal media. Last but not least, recent experimental evidence emphasizes the efficacy of our chemically defined culture media for patient-derived stem cells.